

IMMUNE GLOBULIN APPROVAL PROCESS CHANGE


Date effective: December 7, 2020

Background Information:

Manitoba is one of the highest per capita users of immune globulin products in Canada (40% over that of Ontario and the Atlantic provinces) with a growth rate of 10% per year. Changes are needed to protect the existing supply, as Canadian Blood Services anticipates shortages resulting from reduced plasma collections due to COVID-19. This Targeted Practice Improvement aligns Manitoba with practices in other jurisdictions.

New Process Overview:

Implementation and application of the 2018 Prairie Collaborative Immune Globulin Utilization Management Framework. Detailed Clinical Guideline and other supporting documentation can be found in reference links below. Here is the high level process change:



Recent prescriber document must include the following information:

Diagnosis · Physician indication for immune globulin use · Alternatives tried · Lowest effective dose of immune globulin required · Expected duration of therapy · Clinical response to therapy · Adverse events

Action Required

- Download the updated version of the Request for Release into your EMR/ order copies from the printshop
- Delete/ discard Initial and Follow Up IVIG Request Forms. Submit only the Request for Release and the Prescriber Document)

Work with your clinics/ administration staff to develop processes to enable this lead time

References/Resources:

- <https://sharedhealthmb.ca/health-providers/diagnostic/reference-material>
- <https://apps.sbgf.mb.ca/labmanual/document/requisitions>
- <https://bestbloodmanitoba.ca/for-clinicians/>



Clinical Practice Change issued by:

Dr. Charles Musuka, Medical Director, Transfusion Medicine, Laboratory Services, Shared Health
Dr. Arjuna Ponnampalam, Hematology/Transfusion Medicine, CancerCare Manitoba & Shared Health